Neuronetics SEC Filings

Type
Bericht
Datum
4Insidertransaktion1-4-2026
SCHEDULE 13DSCHEDULE 13D-Formular31-3-2026
4Insidertransaktion30-3-2026
4Insidertransaktion30-3-2026
4Insidertransaktion27-3-2026
4Insidertransaktion24-3-2026
4Insidertransaktion24-3-2026
4Insidertransaktion24-3-2026
4Insidertransaktion23-3-2026
33-Formular23-3-2026
4Insidertransaktion23-3-2026
4Insidertransaktion20-3-2026
144144-Formular19-3-2026
144144-Formular19-3-2026
4Insidertransaktion18-3-2026
4Insidertransaktion18-3-2026
4Insidertransaktion18-3-2026
4Insidertransaktion18-3-2026
33-Formular18-3-2026
SCHEDULE 13G/ASCHEDULE 13G/A-Formular18-3-2026
S-3S-3-Formular17-3-2026
SCHEDULE 13GSCHEDULE 13G-Formular17-3-2026
10-KJahresbericht17-3-2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben17-3-2026
4Insidertransaktion6-3-2026
SCHEDULE 13D/ASCHEDULE 13D/A-Formular4-3-2026
144144-Formular4-3-2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2-3-2026
4Insidertransaktion27-2-2026
4Insidertransaktion27-2-2026
144144-Formular26-2-2026
144144-Formular26-2-2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben25-2-2026
4Insidertransaktion25-2-2026
4Insidertransaktion25-2-2026
4Insidertransaktion18-2-2026
4Insidertransaktion18-2-2026
4Insidertransaktion12-2-2026
4Insidertransaktion12-2-2026
144144-Formular12-2-2026
144144-Formular12-2-2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10-2-2026
144144-Formular10-2-2026
144144-Formular10-2-2026
SCHEDULE 13G/ASCHEDULE 13G/A-Formular4-2-2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben22-1-2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6-1-2026
4Insidertransaktion31-12-2025
4Insidertransaktion31-12-2025
SCHEDULE 13GSCHEDULE 13G-Formular24-11-2025
10-QQuartalsbericht4-11-2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4-11-2025
4Insidertransaktion22-10-2025
4Insidertransaktion22-10-2025
4Insidertransaktion22-10-2025
4Insidertransaktion22-10-2025
4Insidertransaktion12-8-2025
SCHEDULE 13D/ASCHEDULE 13D/A-Formular12-8-2025
144144-Formular8-8-2025
144144-Formular8-8-2025
144144-Formular8-8-2025
144144-Formular7-8-2025
424B5424B5-Formular6-8-2025
10-QQuartalsbericht5-8-2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5-8-2025
EFFECTEFFECT-Formular18-7-2025
CORRESPCORRESP-Formular16-7-2025
33-Formular15-7-2025
4Insidertransaktion15-7-2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben15-7-2025
UPLOADUPLOAD-Formular9-7-2025
S-3S-3-Formular3-7-2025
SDSD-Formular2-6-2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben28-5-2025
4Insidertransaktion27-5-2025
4Insidertransaktion27-5-2025
4Insidertransaktion27-5-2025
4Insidertransaktion27-5-2025
4Insidertransaktion27-5-2025
4Insidertransaktion27-5-2025
4Insidertransaktion14-5-2025
144144-Formular13-5-2025
144144-Formular12-5-2025
10-QQuartalsbericht6-5-2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6-5-2025
DEFA14ADEFA14A-Formular10-4-2025
DEF 14ADEF 14A-Formular10-4-2025
10-KJahresbericht27-3-2025
PRE 14APRE 14A-Formular27-3-2025
8-K/A8-K/A-Formular27-3-2025
4/A4/A-Formular13-3-2025
4/A4/A-Formular13-3-2025
4/A4/A-Formular13-3-2025
4Insidertransaktion6-3-2025
4Insidertransaktion6-3-2025
144144-Formular4-3-2025
144144-Formular4-3-2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4-3-2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4-3-2025
4Insidertransaktion26-2-2025

Neuronetics Documenten 2026

Deze pagina bevat alle officiële documenten en SEC-filings voor Neuronetics aandelen (STIM, ISIN: US64131A1051). Dit omvat jaarverslagen (Formulier 10-K), kwartaalrapporten (Formulier 10-Q) en insidertransacties (Formulier 4). Momenteel zijn 100 documenten beschikbaar. Gegevens worden regelmatig bijgewerkt om beleggers een volledig overzicht van Neuronetics's regelgevingsfilings te bieden.

Neuronetics Aandelenanalyse

Neuronetics Neuronetics Inc is a globally leading company in the field of non-invasive neuromodulatory technology. It was founded in 2003 and is headquartered in Malvern, Pennsylvania. The company specializes in the development and production of transcranial magnetic stimulation devices that can be used in the treatment of psychiatric disorders, particularly severe depression. Neuronetics' business model is based on selling its patented technology, called NeuroStar Advanced Therapy, to medical facilities worldwide. The company works closely with leading psychiatrists and clinical neurophysiologists to ensure that their devices meet the highest quality standards and can provide the best possible help to patients. The company has achieved a number of significant milestones in recent years. For example, in 2008, it received the first FDA approval for its technology. Since then, Neuronetics has continuously developed and improved its technology and has also obtained approvals in Europe and other parts of the world. Neuronetics is divided into various divisions, including research and development, manufacturing, and sales. Each of these departments is focused on ensuring the highest quality standards and ensuring that the technology of NeuroStar Advanced Therapy meets the needs of patients and medical personnel. The technology of NeuroStar Advanced Therapy is based on transcranial magnetic stimulation (TMS), which uses gentle magnetic fields to stimulate the activity of certain brain regions. The stimulation can help restore the balance of neurotransmitters in the brain and thus alleviate depression. Treatment with NeuroStar Advanced Therapy has significant advantages over conventional antidepressant medications. In many cases, it leads to faster improvement of symptoms and does not cause any of the undesirable side effects that can occur with medication. Overall, Neuronetics has developed a revolutionary technology with NeuroStar Advanced Therapy that can help millions of people around the world overcome their depression. The company is proud to contribute to improving the quality of life for people and will continue to develop innovative solutions in the field of neuromodulatory technology in the future.